News Feature
Nature Biotechnology 25, 13 - 16 (2007)
Published online: 5 January 2007 | doi:10.1038/nbt0107-13
The policy outlook from the Hill
Brian Vastag1
- Washington, DC
Abstract
Price controls and a greater role for the US FDA may foreshadow difficult times for the biotech industry in the coming year
